Workflow
Immunovant(IMVT) - 2025 Q4 - Annual Report
IMVTImmunovant(IMVT)2025-05-29 11:30

Drug Development - Immunovant is focused on developing IMVT-1402, a potential best-in-class FcRn inhibitor, to address autoimmune diseases driven by high levels of pathogenic IgG antibodies [502]. - In a Phase 1 clinical trial, IMVT-1402 demonstrated deep, dose-dependent IgG reductions, with expectations to achieve approximately 80% IgG reductions with 600 mg weekly dosing [504]. - The company has initiated studies in five indications for IMVT-1402, including potentially registrational trials in Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy [506]. - Batoclimab's Phase 3 study in myasthenia gravis achieved a 5.6 point mean improvement in the MG-ADL score, with a 93% response rate among AChR+ participants receiving the 680 mg dose [515]. - The Phase 2 proof-of-concept trial for batoclimab in Graves' disease showed a mean IgG reduction of 77% and a 76% response rate after 12 weeks of treatment [510]. - A second potentially registrational trial for IMVT-1402 in Graves' disease is planned to start in summer 2025, enrolling approximately 210 participants [512]. - The company expects to report top-line results from the Phase 3 trial of batoclimab in thyroid eye disease in the second half of calendar year 2025 [513]. - Data from batoclimab studies are being leveraged to inform and accelerate the development of IMVT-1402 [507]. - The Phase 2b trial of batoclimab in chronic inflammatory demyelinating polyneuropathy demonstrated an 84% responder rate in patients achieving at least a 70% IgG reduction [507]. - A potentially registrational trial for IMVT-1402 in CIDP was initiated in March 2025, aiming to enroll approximately 162 participants [521]. - The trial for IMVT-1402 in ACPA-positive D2T RA is expected to enroll approximately 120 participants, with initial results anticipated in 2026 [522]. - A proof-of-concept trial for IMVT-1402 in CLE was initiated in February 2025, with an expected enrollment of approximately 56 participants [524]. - The company plans to initiate a potentially registrational trial for IMVT-1402 in SjD in the summer of 2025, enrolling around 180 participants [523]. Financial Performance - Research and development expenses for the year ended March 31, 2025, increased by 147.99millioncomparedtothepreviousyear,totaling147.99 million compared to the previous year, totaling 360.92 million [540]. - Total operating expenses for the year ended March 31, 2025, were 438.15million,upfrom438.15 million, up from 282.71 million in 2024 [540]. - The net loss for the year ended March 31, 2025, was 413.84million,comparedtoanetlossof413.84 million, compared to a net loss of 259.34 million in 2024 [540]. - General and administrative expenses for the year ended March 31, 2025, were 77.24million,anincreasefrom77.24 million, an increase from 57.28 million in 2024 [540]. - For the year ended March 31, 2025, research and development costs increased by 91.1millioncomparedtotheprioryear,withspecificincreasesinendocrinediseases(91.1 million compared to the prior year, with specific increases in endocrine diseases (29.9 million) and neurological diseases (52.2million)duetoclinicaltrialpreparations[543].−Unallocatedresearchanddevelopmentcostsroseby52.2 million) due to clinical trial preparations [543]. - Unallocated research and development costs rose by 56.9 million, driven by higher personnel-related expenses of 37.2millionandotherexpensesof37.2 million and other expenses of 19.7 million [544]. - General and administrative expenses increased by 20.0millionfortheyearendedMarch31,2025,primarilyduetohigherpersonnel−relatedexpensesandprofessionalfees[550].−Thecompanyhasnotgeneratedanyrevenueandcontinuestoincursignificantoperatinglossessinceinception[530].−AsofMarch31,2025,cashandcashequivalentswere20.0 million for the year ended March 31, 2025, primarily due to higher personnel-related expenses and professional fees [550]. - The company has not generated any revenue and continues to incur significant operating losses since inception [530]. - As of March 31, 2025, cash and cash equivalents were 714.0 million, up from 635.4millioninthepreviousyear,whilenetlosseswere635.4 million in the previous year, while net losses were 413.8 million [552]. - Cash used in operating activities for the year ended March 31, 2025, was 375.9million,reflectinganetlossfromoperationsof375.9 million, reflecting a net loss from operations of 413.8 million [559]. - Cash provided by financing activities for the year ended March 31, 2025, was 454.5million,primarilyfromaprivateplacementthatraised454.5 million, primarily from a private placement that raised 450.0 million [563]. - The company expects to continue incurring significant expenses and increasing operating losses for the next several years, with no revenue generated to date [552]. - The existing cash and cash equivalents of 714.0millionasofMarch31,2025,areexpectedtobesufficienttofundoperatingexpensesandcapitalexpendituresthroughtheGDreadoutanticipatedin2027[570].−Thecompanyanticipatesanincreaseinshort−termandlong−termcapitalrequirementstofundclinicaldevelopmentprogramsandmanufacturingofIMVT−1402[572].−CurrentfundsareinsufficienttocompleteallnecessarydevelopmentandcommerciallaunchofIMVT−1402orbatoclimab,withexpectedcontinuednetlosses[573].MilestonePaymentsandObligations−Thecompanyhasaremainingminimumobligationofapproximately714.0 million as of March 31, 2025, are expected to be sufficient to fund operating expenses and capital expenditures through the GD readout anticipated in 2027 [570]. - The company anticipates an increase in short-term and long-term capital requirements to fund clinical development programs and manufacturing of IMVT-1402 [572]. - Current funds are insufficient to complete all necessary development and commercial launch of IMVT-1402 or batoclimab, with expected continued net losses [573]. Milestone Payments and Obligations - The company has a remaining minimum obligation of approximately 43.6 million to Samsung for batoclimab drug substance manufacturing, with payments scheduled through fiscal year 2030 [568]. - As of March 31, 2025, the maximum potential milestone payments under the HanAll Agreement could reach 420.0million,with420.0 million, with 32.5 million already paid for prior milestones [569]. - The company made a milestone payment of $12.5 million during the quarter ended September 30, 2023, following the achievement of regulatory milestones [569]. Research and Development Strategy - Research and development costs are expensed as incurred, primarily consisting of employee compensation and third-party expenses for clinical trials [576]. - The company plans to integrate acquired technologies, expand its intellectual property portfolio, and hire additional personnel to support drug development efforts [577]. Liquidity and Market Risks - As of March 31, 2025, cash and cash equivalents are maintained in accredited financial institutions, with no material effect on liquidity from a hypothetical 10% change in interest rates [578]. - The company does not currently face significant foreign currency exchange rate risk, as expenses are primarily in U.S. dollars [579]. - Inflation has not had a material effect on the company's business or financial condition as of March 31, 2025 [580].